Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance

Area of Science:

• Pediatric Immunology
• Infectious Disease Management
• Biologic Therapies

Background:

• Biologic response modifiers (BRMs), particularly TNF-α inhibitors, have significantly improved outcomes for pediatric immune-mediated inflammatory diseases.
• While effective, these therapies carry an increased risk of infections, including Mycobacterium tuberculosis.

Purpose of the Study:

• To analyze the heightened risk of tuberculosis (TB) infection and reactivation in children treated with TNF-α inhibitors.
• To provide recommendations for screening, safety monitoring, and preventive therapies for TB in pediatric patients on anti-TNF-α treatment.

Main Methods:

• Review of current literature on TB risk associated with TNF-α inhibitors in pediatric populations.
• Analysis of the utility of available TB screening tools: Interferon-Gamma Release Assays (IGRAs) and Tuberculin Skin Test (TST).
• Evaluation of recommended TB preventive strategies and management of anti-TB and anti-TNF-α treatment overlap.

Main Results:

• Children on TNF-α inhibitors face an elevated risk of de novo TB infection and reactivation of latent TB infection (LTBI).
• IGRAs and TST are crucial for diagnosing LTBI before initiating and during biologic therapy.
• Specific TB preventive therapies and optimized treatment timing are essential for patient safety.

Conclusions:

• Proactive screening for LTBI is critical in pediatric patients commencing TNF-α inhibitor therapy.
• Continuous monitoring and timely intervention are necessary to mitigate TB risks in this vulnerable population.
• Adherence to screening protocols and preventive measures can ensure the safe and effective use of BRMs.